TreatSMA exclusive webinar with respiratory expert Dr John Bach
A couple of weeks ago we had the honour of hosting Dr John Bach for an exclusive webinar looking at how to manage the respiratory system of SMA sufferers.
Category: Updates
Roche release new data on infants, children and adults
Roche have released new data which shows that Risdiplam significantly improves motor function after 24 months in people between the ages of 2 and 25 years, this includes both type 2 and type 3 patients. In addition the data also shows that after 12 months of patients previously treated he continues to show a rapid…
Roche release new data on infants, children and adults
Roche have released new data which shows that Risdiplam significantly improves motor function after 24 months in people between the ages of 2 and 25 years, this includes both type 2 and type 3 patients. In addition the data also shows that after 12 months of patients previously treated he continues to show a rapid…
Further Clarity on Access to Compassionate Use Program for Risdiplam.
We have received further clarity statement from the NHS England Clinical Panel for nusinersen with regards to access compassionate program for Risdiplam.
Further Clarity on Access to Compassionate Use Program for Risdiplam.
We have received further clarity statement from the NHS England Clinical Panel for nusinersen with regards to access compassionate program for Risdiplam.
A Big Thank You and Fond Farewell to Dedicated Trustee
It is with great sadness we announce the departure of Kacper from the TreatSMA team.